Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 1
1984 1
1986 1
1987 3
1990 1
1991 2
1994 1
1996 2
1998 2
2002 1
2003 2
2004 2
2005 1
2008 1
2009 1
2010 1
2013 1
2016 1
2017 3
2018 1
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies.
O'Donnell JN, Rhodes NJ, Miglis CM, Catovic L, Liu J, Cluff C, Pais G, Avedissian S, Joshi MD, Griffin B, Prozialeck W, Gulati A, Lodise TP, Scheetz MH. O'Donnell JN, et al. Among authors: cluff c. Int J Antimicrob Agents. 2018 Feb;51(2):239-243. doi: 10.1016/j.ijantimicag.2017.08.012. Epub 2017 Aug 10. Int J Antimicrob Agents. 2018. PMID: 28803934 Free PMC article. Review.
24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.
O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Miglis CM, Joshi MD, Venkatesan N, Pais G, Cluff C, Lamar PC, Briyal S, Day JZ, Gulati A, Scheetz MH. O'Donnell JN, et al. Among authors: cluff c. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e00416-17. doi: 10.1128/AAC.00416-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28807910 Free PMC article.
Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury.
Pais GM, Avedissian SN, O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Lamar PC, Cluff C, Gulati A, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH. Pais GM, et al. Among authors: cluff c. Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00079-19. doi: 10.1128/AAC.00079-19. Print 2019 Jul. Antimicrob Agents Chemother. 2019. PMID: 30988153 Free PMC article.
The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics.
Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, Bess LS, Livesay MT, Arnold JS, Johnson CL, Ryter KT, Cluff CW, Evans JT, Johnson DA. Bazin HG, et al. Among authors: cluff cw. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4. doi: 10.1016/j.bmcl.2008.09.060. Epub 2008 Sep 19. Bioorg Med Chem Lett. 2008. PMID: 18835160
Structure-activity relationship of synthetic toll-like receptor 4 agonists.
Stöver AG, Da Silva Correia J, Evans JT, Cluff CW, Elliott MW, Jeffery EW, Johnson DA, Lacy MJ, Baldridge JR, Probst P, Ulevitch RJ, Persing DH, Hershberg RM. Stöver AG, et al. Among authors: cluff cw. J Biol Chem. 2004 Feb 6;279(6):4440-9. doi: 10.1074/jbc.M310760200. Epub 2003 Oct 21. J Biol Chem. 2004. PMID: 14570885 Free article.
Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.
Michaud JP, Hallé M, Lampron A, Thériault P, Préfontaine P, Filali M, Tribout-Jover P, Lanteigne AM, Jodoin R, Cluff C, Brichard V, Palmantier R, Pilorget A, Larocque D, Rivest S. Michaud JP, et al. Among authors: cluff c. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1941-6. doi: 10.1073/pnas.1215165110. Epub 2013 Jan 15. Proc Natl Acad Sci U S A. 2013. PMID: 23322736 Free PMC article.
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
Westaway SM, Brown SL, Fell SC, Johnson CN, MacPherson DT, Mitchell DJ, Myatt JW, Stanway SJ, Seal JT, Stemp G, Thompson M, Lawless K, McKay F, Muir AI, Barford JM, Cluff C, Mahmood SR, Matthews KL, Mohamed S, Smith B, Stevens AJ, Bolton VJ, Jarvie EM, Sanger GJ. Westaway SM, et al. Among authors: cluff c. J Med Chem. 2009 Feb 26;52(4):1180-9. doi: 10.1021/jm801332q. J Med Chem. 2009. PMID: 19191554
29 results